Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial

Date
2021
Author
Spigel, David
Uslu, Ruchan
Krzakowski, Maciej
Lee, Jong-Seok
Calabro, Luana
Frontera, Osvaldo Aren
Xiong, Huiling
Bajars, Marcis
Ruisi, Mary
Barlesi, Fabrice
Park, Keunchil
ÖZGÜROĞLU, Mustafa
Vansteenkiste, Johan
Yang, James C. H.
Ishii, Hidenobu
Garassino, Marina
de Marinis, Filippo
Szczesna, Aleksandra
Polychronis, Andreas
Metadata
Show full item record
Abstract
Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data.
URI
http://hdl.handle.net/20.500.12627/175331
https://doi.org/10.1016/j.jtho.2021.03.009
Collections